ASHLEY JOHNSON: Open Payments
NPI 1619620614 · MCKINNEY, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,476 in 63 payments from 20 companies in 2025. Trend: 2023 $1,748 · 2024 $1,495 · 2025 $1,476
Food & beverage: $1,476
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 5 | $204 |
| Amgen Inc. | 11 | $187 |
| Otsuka America Pharmaceutical, Inc. | 7 | $155 |
| Calliditas Therapeutics US Inc. | 9 | $151 |
| Alnylam Pharmaceuticals Inc. | 1 | $108 |
| AstraZeneca Pharmaceuticals LP | 5 | $108 |
| Travere Therapeutics, Inc. | 3 | $89 |
| Ardelyx, Inc. | 4 | $88 |
| Genentech USA, Inc. | 3 | $60 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $56 |
Products named: Ozempic, JYNARQUE, TARPEYO, KRYSTEXXA, AMVUTTRA, FARXIGA, IBSRELA, Kerendia.
Industry payments across TX — which companies pay providers there.
